ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.